Company / Return on Equity (ROE)
Mineralys Therapeutics, Inc. Return on Equity (ROE) History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-93.0%
FY2024
5-year range
-93.0% / -29.8%
FY2023-FY2024
Trend
-211.9%
vs FY2023
Sector context
#164 of 190
Health Care
What the data says
Mineralys Therapeutics, Inc. reports negative total equity of -93.0% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-93.0% in FY2024.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 190This company -93.0% Sector average -50.3%
▼
-84.8% below sector average
Key checks
Key Insights
- In FY2024, return on equity (roe) decreased 211.9% year-over-year.
- Currently 42.7pp below the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -93.0% | -211.9% |
| FY2023 | -29.8% | - |
| FY2022 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026